Post-Doctoral Research Fellow, Tumor Dormancy & Metabolism
Fred Hutchinson Cancer Research Center
Location: Seattle, Washington
Internal Number: 19044
Fred Hutchinson Cancer Center is an independent, nonprofit, unified adult cancer care and research center that is clinically integrated with UW Medicine, a world leader in clinical care, research and learning. The first National Cancer Institute-designated cancer center in the Pacific Northwest, Fred Hutch's global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy, and COVID-19 vaccines has confirmed our reputation as one of the world's leading cancer, infectious disease and biomedical research centers. Based in Seattle, Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy, and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world's deadliest diseases and make life beyond cancer a reality.
At Fred Hutch, we believe that the innovation, collaboration, and rigor that result from diversity and inclusion are critical to our mission of eliminating cancer and related diseases. We seek employees who bring different and innovative ways of seeing the world and solving problems. Fred Hutch is in pursuit of becoming an antiracist organization. We are committed to ensuring that all candidates hired share our commitment to diversity, antiracism, and inclusion.
A laboratory in Fred Hutchinson Cancer Research Center's Translational Research Program (Public Health Sciences Division) is looking for a highly motivated Postdoctoral Research Fellow to study the metabolism of dormant, disseminated tumor cells (DTCs). The candidate would join the Laboratory for the Study of Metastatic Microenvironments (LSM2), directed by Cyrus Ghajar. The LSM2 focuses on understanding the biology underlying DTC dormancy (see: Carlson et al., Nature Cell Biology 2019; Goddard et al., Nature Cell Biology 2018; Ghajar et al., Nature Cell Biology 2013) and uncovering means to eradicate dormant DTCs. Our overarching goal is to develop therapeutically viable approaches to prevent breast cancer metastasis.
The candidate will spearhead a project with the goals of:
Measuring the metabolic state of dormant disseminated breast cancer cells across tissues
Determining whether DTCs face common or tissue-specific bottlenecks as they colonize distant sites (eg, brain, lung, bone marrow/bone, liver)
Understanding, developing, and trialing therapies exploiting potential metabolic vulnerabilities of dormant DTCs with the goal of preventing breast cancer metastasis
The ideal candidate will be able to take advantage of a resource-rich environment to develop an innovative and comprehensive strategy to understand metabolic requirements of DTCs, spanning dormancy, micrometastases, and metastatic colonization. They will be expected to take advantage of unique resources, including human specimens derived from rapid autopsy, immune-competent animal models, and organotypic culture.
An interest and passion in developing curative approaches for metastasis is required. A strong publication record and eligibility and desire to apply for future fellowships are also required. A Ph.D. and demonstrated expertise in metabolism (whether physiologic or pathologic/cancer) is absolutely desired. The candidate must also be experienced in essential techniques to characterize and report on metabolism of a given cell. A candidate with experience in live cell imaging, bioinformatics (e.g., analysis of metabolomic data), and/or experience working in murine tumor or metastasis models is strongly desired.
The successful candidate will contribute positively to our lab's environment. They must have excellent communication and organizational skills, the ability to develop creative approaches to experimental design, and thrive both in independent research and while working collaboratively.
Fred Hutch has a mandatory COVID-19 vaccine requirement, with exceptions only for approved medical or religious accommodations. As a condition of employment, newly hired employees must provide proof of vaccination or initiate the accommodations process before their first day of employment.
A statement describing your commitment and contributions toward greater diversity, equity, inclusion, and anti-racism in your career or that will be made through your work at Fred Hutch is requested of all finalists.
Our Commitment to Diversity
We are proud to be an Equal Employment Opportunity (EEO) and Vietnam Era Veterans Readjustment Assistance Act (VEVRAA) Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability (physical or mental), marital or veteran status, genetic information, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at email@example.com or by calling 206-667-4700.
At Fred Hutchinson Cancer Research Center, teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Researchers are discovering new ways to detect cancers earlier, improve treatments, and learn how to prevent cancers from growing. Although Fred Hutchinson opened its doors in 1975, its history began about 20 years before that. In 1962 Fred Hutchinson envisioned a center devoted to studying cancer, a disease that took his brother’s life. Today Fred Hutchinson is contributing to the next waves of breakthrough treatments and prevention strategies. Fred Hutchinson collaborates with the Seattle Cancer Alliance, the National Cancer Institute, and the University of Washington.